文献速递免疫规划慢病防控与筛查卫生政策与健康促进

中国老年慢性阻塞性肺疾病患者23价肺炎链球菌多糖疫苗接种试点规划的健康经济学评价

[Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2016-01-01

从健康经济学角度评价慢性阻塞性肺疾病(COPD)患者接种23价肺炎链球菌多糖疫苗的试点规划。在四个试点县以非概率抽样选取860名60岁以上、近一年因COPD急性加重住院且3年内未接种该疫苗的参合对象,2013年1—12月接种,2014年1月起随访一年。接种后人均因急性加重减少1.12±2.51次治疗,人均节省医疗费用3610.21元,人均获得0.03 QALY,ICER为优势,成本效益比为12.00,作者建议在有条件地区将该疫苗纳入公共卫生规划或医保。

要点

  • 接种后人均因COPD急性加重减少1.12±2.51次治疗,其中门诊减少0.28±2.09次、住院减少0.85±1.15次。
  • 人均节省医疗费用3610.21元,其中门诊费用241.41元、住院费用269.82元;人均获得0.03 QALY。
  • ICER为优势,成本效益比为12.00;作者建议有条件地区将该疫苗纳入公共卫生规划或医保。

核心结论

  • COPD患者接种23价肺炎链球菌多糖疫苗后一年内因急性加重减少治疗次数,接种具有成本效果且节省成本。
  • 作者建议在有条件地区将该疫苗纳入公共卫生规划或医保方案。

研究设计与样本

  • 采用无对照组的准实验设计,在COPD患者整合照护路径项目试点县(陕西汉中市汉滨区、重庆庆庆市黔江区、山东青岛市环岛区、河南焦作市温县)开展。
  • 通过当地新型农村合作医疗信息系统收集参合者的一般信息及医疗记录和医疗费用。
  • 采用非概率抽样选取860名60岁以上、当地户籍、近一年因COPD急性加重住院且3年内未接种23价肺炎链球菌多糖疫苗的对象。
  • 对象于2013年1—12月接种23价肺炎链球菌多糖疫苗,2014年1月起随访一年。
  • 采用自设问卷和中文版欧洲五维健康量表收集效果与医疗费用数据,采用配对秩和检验比较干预前后一年因COPD急性加重的生活质量、治疗次数及直接医疗费用(含门诊和住院)。

主要发现

  • 截至2014年1月,860名对象完成接种;截至2015年1月,788名对象完成随访,72例退出(8.4%)。
  • COPD患者平均因急性加重减少1.12±2.51次治疗,其中门诊治疗减少0.28±2.09次、住院减少0.85±1.15次。
  • 人均节省医疗费用3610.21元,其中门诊费用241.41元、住院费用269.82元。
  • 人均获得0.03 QALY。
  • ICER为优势,CBR为12.00。

临床怎么用

  • 作者建议在有条件地区将该疫苗纳入公共卫生规划或医保方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: From the perspective of health economics, to evaluate 23 pneumococcal polysaccharide vaccination programme among chronic obstructive pulmonary disease (COPD) patient. Methods: In the pilot counties of the project of integrated care pathway for COPD patient (Hanbin district of Hanzhong city in Shanxi Province, Qianjian district of Qingqing city, Huandao district of Qindao city in Shangdong Province, Wen county of Jiaozuo city in Henan Province), information of insurance participants of New Rural Cooperative Medical System (NRCS) was collected by local NRCM information system, which included general information as well as records of medical care and medical fee. Nonprobability sampling method was applied to select a total of 860 objects, who were over 60 years old with local household registration, hospitalized within one recent year due to COPD acute exacerbation, and without vaccination of 23 voluntary pneumococcal polysaccharide vaccine within 3 years. A quasi-experimental design without control group was adopted. Objects were vaccinated with 23-valent pneumococcal polysaccharide vaccine from January to December in 2013, then were followed up from January in 2014 for one year. Data of effectiveness and medical cost was collected by self-designed questionnaire and <EuroQol five dimensions questionnaire >(Chinese version). Paired rank sum test applied to test the difference of quality of life, number and direct medical cost of treatment (including outpatient treatment and hospitalization) due to COPD acute exacerbation, one year before and after intervention. The incremental cost-effectiveness ratio (ICER) and cost-benefit ratio (CBR) of the programme were calculated. Results: By January 2014, eight hundred sixty objects were vaccinated. By January 2015, seven hundred eighty eight objects were followed up, with 72 cases withdrawed (8.4%). On average, COPD patients reduced 1.12±2.51 treatments due to acute exacerbation, including 0.28±2.09 outpatient treatments and 0.85±1.15 hospitalizations. Total medical cost was saved by 3 610.21 per capita yuan, including outpatient cost of 241.41 yuan and hospitalization cost of 269.82 yuan; Quality of life was gained by 0.03 QALY gain per capita. The ICER was dominant and CBR was 12.00. Conclusion: COPD patients vaccinated with 23-valent pneumococcal polysaccharide vaccine within one year reduced treatments due to acute exacerbation. The vaccination was cost effective and cost saving , and we suggest the vaccine should be covered in the public health program or health insurance scheme in conditional region.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qiu YP, Zhao K, Li X, et al. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2016. PMID: 28057111. doi:10.3760/cma.j.issn.0253-9624.2016.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。